...
首页> 外文期刊>British Journal of Clinical Pharmacology >Particle size and gastrointestinal absorption influence tiotropium pharmacokinetics: a pilot bioequivalence study of PUR0200 and Spiriva HandiHaler
【24h】

Particle size and gastrointestinal absorption influence tiotropium pharmacokinetics: a pilot bioequivalence study of PUR0200 and Spiriva HandiHaler

机译:粒径和胃肠道吸收影响Tiotropium药代动力学:PUR0200和Spiriva HandiHaler的试验生物等效研究

获取原文
获取原文并翻译 | 示例
           

摘要

Aims Plasma pharmacokinetics permit the assessment of efficacy and safety of inhaled drugs, and possibly their bioequivalence to other inhaled products. Correlating drug product attributes to lung deposited dose is important to achieving equivalence. PUR0200 is a spray-dried formulation of tiotropium that enables more efficient lung delivery than Spiriva((R)) HandiHaler((R)) (HH). The ratio of tiotropium lung-to-oral deposition in PUR0200 was varied to investigate the impact of particle size on tiotropium pharmacokinetics, and the contribution of oral absorption to tiotropium exposure was assessed using charcoal block. Methods A seven-period, single-dose, crossover study was performed in healthy subjects. PUR0200 formulations differing in dose and aerodynamic particle size were administered in five periods and Spiriva HH in two periods. In one period, Spiriva HH gastrointestinal absorption was blocked with oral charcoal. Tiotropium plasma concentrations were assessed over 8 h after inhalation. Results PUR0200 pharmacokinetics were influenced by aerodynamic particle size and the ratio of lung-to-oral deposition, with impactor sized mass (ISM) correlating most strongly with exposure. Formulation PUR0217a (3 mu g tiotropium) lung deposition was similar to Spiriva HH (18 mu g) with and without charcoal block, but total PUR0200 exposure was lower without charcoal. The C-max and AUC(0-0.5h) of Spiriva HH with and without charcoal block were bioequivalent; however, Spiriva HH AUC(0-8h) was lower when gastrointestinal absorption was inhibited with oral charcoal administration. Conclusions Pharmacokinetic bioequivalence indicative of lung deposition and efficacy can be achieved by matching the reference product ISM. Due to reduced oral deposition and more efficient lung delivery, PUR0200 results in a lower AUC(0-t) than Spiriva HH due to reduced absorption of drug from the gastrointestinal tract.
机译:AIMS血浆药代动力学允许评估吸入药物的功效和安全性,以及它们对其他吸入产品的生物等效性。将药物产品属性与肺沉积的剂量相关,对实现等价是重要的。 PUR0200是一种干燥的噻托尼亚的干燥制剂,其能够比绣线虫((r))手机((r))(hh)更有效的肺部递送。硫铵肺对口腔沉积在PUR0200中的比例变化,以研究粒度对噻托溴铵药代动力学的影响,并使用木炭嵌段评估口腔吸收对噻托溴铵暴露的贡献。方法在健康受试者中进行七期,单剂量交叉研究。在两个时期的五个时期和刺激HH中施用多种剂量和空气动力学粒度的制剂。在一个时期,肌肉胃肠胃肠吸收与口服炭封闭。吸入后8小时评估噻托溴酸血浆浓度。结果PUR0200药代动力学受气动粒度的影响和肺对口沉积的比例,抗冲击力大小(ISM)与暴露最强烈地相关。配方PUR0217A(3μg噻托溴铵)肺沉积与螺旋HH(18μg)相似,没有木炭嵌段,但在没有木炭的情况下,总pUS0200暴露较低。有没有木炭块的Spiriva Hh的C-Max和Auc(0-0.5h)是生物等效;然而,当用口服木炭给药抑制胃肠道吸收时,Spiriva HH AUC(0-8H)较低。结论通过匹配参考产物ISM,可以实现指示肺沉积和功效的药代动力学生物等效性。由于口服沉积和更有效的肺部递送,PUR0200导致较低的AUC(0-T),而不是胃肠道吸收药物的吸收。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号